18 drugs nationwide stop supply! 4.5 billion varieties are listed.

Pharmaceutical network October 23rd, October 21st, Shanxi Province drug weapons centralized bidding procurement network has hung up two drugs to withdraw the network publicity.
combed, 18 pharmaceutical product regulations of 13 pharmaceutical companies applied for revocation of centralized procurement of winning products / directly hanging online product platform registration qualification.
s initiative to withdraw the network into the normal according to enterprise applications, in accordance with the "Shanxi Province 2015 public medical institutions centralized classification of drug procurement regulations" related provisions, Jilin I Zheng Pharmaceutical Group Co., Ltd. and other 6 pharmaceutical production enterprises 8 drug product regulations, apply for the withdrawal of centralized procurement winning bid Product platform hanging network qualification, and provide a unified national commitment not to supply, Zhengda Youth Bao Pharmaceutical Co., Ltd. and other 8 pharmaceutical production enterprises 10 drug product regulations, apply for the revocation of direct hanging network product platform registration qualification, and provide a unified national non-supply commitment.
fact, enterprises take the initiative to withdraw the hanging network and commitment to the national unity of non-supply, which in Shanxi Province drug concentrated bidding procurement network can be said to be a common thing.
This year alone, has announced two batches, a total of 92 product regulations actively withdraw the hanging network: in May, Zhejiang Yongning Pharmaceutical Co., Ltd. and other 14 pharmaceutical production enterprises 44 drug product regulations applied to revoke the direct hanging network product platform registration qualification, Chengdu Geo Pharmaceutical Group Co., Ltd. and other 11 pharmaceutical production enterprises 22 drug regulations Application to revoke the centralized procurement of the winning product platform registration qualification, in August, Chongqing Doputai Pharmaceutical Co., Ltd. and other 8 pharmaceutical production enterprises 13 drug product regulations apply to revoke the direct hanging network product platform registration qualification, Shanxi Pude Pharmaceutical Co., Ltd. and other 8 pharmaceutical production enterprises 13 drug product regulations, apply for the withdrawal of centralized procurement of the winning product platform registration qualification.
analysts pointed out that the small amount of procurement and price inverted is the incentive for enterprises to actively apply for the withdrawal of the network, especially in the collection of continuous price reduction, clinical control fees and raw material prices and other multiple pressures, pharmaceutical companies can only take the initiative to abandon the bid, withdrawal of the network.
Although the products involved after the withdrawal of the network can not be sold in public hospitals through provincial collection platforms, but still through retail pharmacies, e-commerce platforms or private hospitals and other channels to sell - of course, the market space is still compressed, the impact of injections is particularly obvious.
the effect of collecting and changing blood gradually? Among the 18 drug regulations announced in the two notices, Shanxi involves several injection varieties such as sodium serotonin for injection, sodium sodium sulphate for hydrogenation for injection, cephalosporine for injection, sodium cephalosporine for injection, nieme cornelin for injection, sodium aweitate for injection, sodium heparin injection, etc.
cephalosporine for injections and sodium cephalosporine for injections are large varieties that sell billions of dollars a year, all in the queue for top 20, a terminal drug injection in public medical institutions, last year.
, sodium cephalosporine for injection is one of the 21 varieties purchased as injection belt volume in Shanxi Province because of clinical maturity, large procurement amount and relatively full competition.
2019, China's public medical institutions terminal sales reached 4.48 billion yuan.
the number of enterprises that have passed the Shanxi injection collection qualification examination have as many as 23.
in the case of cephalosporine for injection, the volume purchase rewrites the market pattern of the variety in Shanxi.
In accordance with the provisions of the "Shanxi Province Medical Institutions First Drug Group Alliance Centralized Band Volume Procurement Document", in accordance with the procurement alliance medical institutions in the 2019 year selected products generic name drug Shanxi Province pharmaceutical procurement platform procurement of 70% of the total procurement volume as the agreed procurement volume.
In other words, the then-selected Luoxin Pharmaceuticals directly received 70% of the total procurement volume (1.0g specification 1135263 bottles, 2.0g specification 233645 bottles), Shanxi Province injection cephalosporine sodium procurement volume Top 1 enterprise.
industry sources pointed out that although the enterprise's initiative to withdraw the network is not the main specifications of these two products, but it may also be seen in the provinces in the first injection belt procurement of the first Shanxi market "blood change" effect can not be underestimated.
combined with the current provincial dynamics, it is expected that the impact of collection on injections will continue to be magnified.
2019, China's public medical institutions terminal injection market size exceeded 630 billion yuan, Top 20 products total sales of more than 100 billion yuan.
, but the industry generally believes that the injection market growth rate is slowing significantly due to factors such as harvesting.
.